Orphan Drug Status Granted to First-in-Class Sarcoidosis Treatment

A clinical developmental program for ARA 290 is being investigated by Araim
A clinical developmental program for ARA 290 is being investigated by Araim

Araim Pharmaceuticals announced that the Food and Drug Administration (FDA) has granted Orphan Drug designation to the investigational agent, ARA 290, for the treatment of sarcoidosis.

Sarcoidosis, an uncommon inflammatory disorder, is a chronic and progressive systemic granulomatous disease affecting multiple organ systems and often presenting with severe and disabling signs and symptoms. Currently, no FDA-approved therapies are available. 

Related Articles

The company is currently investigating ARA 290 in a clinical developmental program for the treatment of sarcoidosis-associated small fiber neuropathy (SFN) and for its potential for disease modification and long-term functional improvement in sarcoidosis.

ARA 290 is a first-in-class synthetic 11-amino acid peptide innate repair receptor (IRR) activator.

For more information visit Araimpharma.com.

Loading links....